Clinical Trials Logo

Pleural Effusion, Malignant clinical trials

View clinical trials related to Pleural Effusion, Malignant.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05372055 Completed - Clinical trials for Malignant Pleural Effusion

Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients

MY-IPC
Start date: May 9, 2022
Phase:
Study type: Observational

The purpose of this study is to better understand the impact that Indwelling Pleural Catheters have on patients with malignant pleural effusions from a psychosocial point of view.

NCT ID: NCT04749602 Completed - Clinical trials for Non-small Cell Lung Cancer Metastatic

Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.

Start date: August 10, 2020
Phase: Phase 2
Study type: Interventional

Patients with advanced cancers who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immunotherapy. The pleura also acts as a natural barrier that can limit the penetration of immune checkpoint inhibitors. In this multicenter phase 2 study, the preliminary efficacy and toxicity of intrapleural instillation of the nivolumab in patients with immune-sensitive metastatic cancers will be accessed.

NCT ID: NCT04264325 Completed - Lung Neoplasms Clinical Trials

Quantitative Diaphragmatic Ultrasound Evaluation in Pleural Effusions : A Feasability Study

ADD-Echo
Start date: January 31, 2020
Phase:
Study type: Observational

Malignant pleural effusions cause breathlessness and impairs quality of life. Thoracocentesis is frequently used to relieve breathlessness. The severity of breathlessness correlates poorly with the size of the effusion. Symptom reduction from fluid drainage varies between patients. No predictors exist to identify which patients benefits more of pleural effusion. One study suggests that a inverted hemidiaphramatic (inverted shape) is associated with a greater dyspnea improvement. Others parameters of diaphragmatic motion have not been studied till now. This study aims to evaluate the feasability of diaphragmatic ultrasound evaluation (shape by B-mode, quiet, deep inspiratory motion and sniff diaphragm motion by TM-mode) before and after pleural drainage. Primary end point aims to evaluate the feasability of deep breath inspiratory excursion in ipsilateral side of thoracocentesis by anterior subcostal approach in the mid-clavicular line in the right in patients with malignant pleural effusions. The liver or spleen was identified as a window for each hemidiaphragm. Secondary end points aim to evaluate - the feasability of quiet breath inspiratory motion , - the feasability of sniff diaphragm motion - the feasability of deep breath inspiratory motion by posterior method - the comparaison of feasibility with different types of breathing and or anterior or posterior approach for ultrasound - the feasability of the shape by B-mode. - the correlation between the change of the shape of ipsilateral diaphragm and the evolution of dyspnea, before and after thoracocentesis. - the correlation between the volume of pleural effusion evacuated and the evolution of dyspnea, before and after thoracocentesis. - the comparaison of the changing of dyspnea in patients with noticed paradoxal movement of diaphragm before thoracocentesis and patients with persistent paradoxal/or non persistant paradoxal movement of ipsilateral hémidiaphragm. - the correlation between the feasability of diaphragmatic ultrasound motion measurments evaluation and the body mass index. - the comparaison between the different diaphragmatic ultrsound times for anterior or posterior approach.

NCT ID: NCT04235998 Completed - Pleural Effusion Clinical Trials

Value of Additional Upfront Systematic Lung Ultrasound in the Workup of Patients With Unilateral Pleural Effusion

Start date: February 17, 2020
Phase:
Study type: Observational

The value of lung ultrasound in the work up of pleural effusion (fluid in between the thin doublet layered film surrounding the lungs) is unknown. The researchers will perform a systematic lung ultrasound scan including a scan for extra thoracic metastasis (spread of cancer to other organs) in the lymphnodes of the neck and metastasis lever in 56 patients one-sided pleural effusion. The researchers will measure if the interventions change the diagnostic plan for the patient and leads to faster diagnostics of the underlying course.

NCT ID: NCT04123886 Completed - Clinical trials for Malignant Pleural Effusion

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

Start date: January 8, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of single dose of SCB-313 by intrapleural injection.To evaluate the safety and tolerability of repeated dose of SCB-313 by intrapleural injection once a day for 3 days, and to determine the maximum tolerated dose (MTD) of SCB-313.

NCT ID: NCT03869697 Completed - Clinical trials for Malignant Pleural Effusions

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

Start date: November 20, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via intrapleural injection (SAD) and once daily over 2 to 3 days (MAD)for the treatment of cancer patients with symptomatic malignant pleural effusions requiring drainage.

NCT ID: NCT03597828 Completed - Clinical trials for Pleural Effusion, Malignant

Respiratory Function of Dexmedetomidine in Patients Undergoing Pleuroscopy

Start date: August 5, 2018
Phase:
Study type: Observational

The primary objective of this prospective trial will be to assess the effects of dexmedetomidine administration on oxygenation and respiratory function in patients undergoing diagnostic or therapeutic medical thoracoscopy/pleuroscopy for a pleural effusion compared to conventional conscious sedation/monitored anesthesia care (MAC) with midazolam. The secondary endpoint of the study will be to also assess the effects of dexmedetomidine administration on respiratory mechanics and postprocedural complications

NCT ID: NCT03414905 Completed - Clinical trials for Malignant Pleural Effusion

Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System

Start date: July 9, 2018
Phase:
Study type: Observational

In this study, the investigators will collect data on patients who are using the Aspira system as part of their clinical care for the management of recurrent pleural effusion. Data will be collected on patient demographics, placement of the pleural catheter, palliation of dyspnea, complication rates, and rates of spontaneous pleurodesis.

NCT ID: NCT03394105 Completed - Clinical trials for Pleural Effusion, Malignant

Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer

Start date: July 26, 2016
Phase: Phase 2
Study type: Interventional

In this trial, the effect of intrapleural docetaxel administration using medical pleuroscopywill be evaluated in Lung Cancer patient with malignant effusion.

NCT ID: NCT03276715 Completed - Lung Cancer Clinical Trials

Prognostic Factors on Malignant Pleural Effusion

Start date: June 1, 2016
Phase:
Study type: Observational [Patient Registry]

Malignant pleural effusion can occur in up to half of the patients with metastatic disease. It can cause shortness of breath to patients and so far there is no protocol on its management. The study is looking at patients with malignant pleural effusion and aims to identify its prognostic factors. Pleural fluid and blood analysis will be performed as in the standard of care and results will be collected at the start of diagnosis. This will not affect subsequent management plan. Patients' disease course will be followed up and progress data will be collected. Data will then be analysed to identify relevant prognostic factors.